Treatments for Bipolar I Disorder—Leveraging Efficacy and Tolerability

Distance Training Glossary | Print Version | Email This Page To A Friend

Training Details

Event Dates and Timeframe
Any Time
Location and Delivery Method
Delivery Method
Online / Web Delivered
Cost Range
FREE
Supported by an educational grant from Alkermes, Inc.

Host And Instructor

Host
Psychiatry & Behavioral Health Learning Network
Instructor
Joseph F. Goldberg, MD and Roger S. McIntyre, MD, FRCPC
class/provider logo image

Credits

C.E. Credit for North American Center for Continuing Medical Education, LLC (NACCME): 1.50
Specialization: 1.50 APA 1.50 CME 1.50 CNE 1.50 Participation 1.50 Pharmacology
North American Center for Continuing Medical Education, LLC (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
C.E. Credit for BH/SW - Association of Social Work Boards (ASWB - ACE): 1.50
NACCME is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NACCME maintains responsibility for this course. Social workers completing this course receive 1.5 Intermediate continuing education credits.

Training Overview Description

We would like to invite you to participate in this new webcast on the treatment of bipolar I disorder (BPI).

This accredited, on-demand activity compares the relative efficacy and side effect profiles of atypical antipsychotics approved for the treatment of BPI, and examines data from late-stage investigational medications.

Event-specific Details

INTENDED LEARNERS
This activity is intended for psychiatrists, primary care physicians, psychologists, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.

LEARNING OBJECTIVES
After completing this activity, participants should be able to:

  • Compare the relative efficacy and side effect profiles of atypical antipsychotics approved for the treatment of BPI
  • Evaluate efficacy and safety data for late-stage investigational medications for the treatment of BPI
  • Demonstrate greater confidence in developing effective and tolerable maintenance strategies for patients with BPI

ACTIVITY OVERVIEW
To be eligible for documentation of credit, participants must participate in the full activity, and complete the evaluation form. Participants who successfully complete the evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Expiration Date: 10/15/2021

For questions regarding this educational activity, please call 609-371-1137.

Registration Information

CLICK HERE TO REGISTER for Treatments for Bipolar I Disorder—Leveraging Efficacy and Tolerability

Funding: Grant funded by the Alaska Mental Health Trust Authority through the University of Alaska Anchorage Center for Human Development.

UAA is an AA/EO employer and educational institution and prohibits illegal discrimination against any individual: http://alaska.edu/titleIXcompliance/nondiscrimination

UA is committed to providing accessible websites. Learn more about UA's notice of web accessibility.